Valuation: Polaris Group

Market Cap 8.88B 279M 245M 232M 210M 395M 26.78B 398M 2.78B 1.07B 13.67B 1.05B 1.02B 43.91B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 9.39B 295M 260M 246M 223M 418M 28.34B 421M 2.94B 1.14B 14.46B 1.11B 1.08B 46.47B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day+0.20%
Current month-7.29%
1 month-11.43%
3 months-20.64%
6 months-49.39%
Current year-68.10%
1 month 9.88
Extreme 9.88
11.25
Current year 9.88
Extreme 9.88
35.95
1 year 9.88
Extreme 9.88
38.4
3 years 9.88
Extreme 9.88
81.9
5 years 9.88
Extreme 9.88
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 2019-02-28
Chief Operating Officer - 2019-01-31
Chief Executive Officer - 2014-04-30
Director TitleAgeSince
Chairman 64 2014-11-23
Director/Board Member - 2020-02-24
Director/Board Member - 2020-01-02
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%0.00%-73.26%-87.52% 279M
+2.64%+6.45%+11.87%+38.40% 47.97B
+0.22%+0.40%+50.91%+37.06% 44.5B
-1.58%+4.66%+359.34%+614.38% 43.93B
+1.70%+0.36%+12.56%+99.27% 41.03B
+0.51%-1.71%+5.18%+46.87% 29.85B
-0.48%-1.32%+23.98%+150.01% 17.27B
+0.08%+9.03%+8.41% - 15.34B
+1.76%+0.85%+29.13%+48.42% 15.3B
+1.97%-3.17% - - 14.82B
Average +0.70%+1.20%+47.57%+118.36% 27.03B
Weighted average by Cap. +0.74%+1.89%+79.30%+163.50%

Financials

2024 2025
Net sales 107M 3.36M 2.96M 2.8M 2.54M 4.76M 323M 4.79M 33.49M 12.93M 165M 12.63M 12.35M 529M 40.6M 1.28M 1.12M 1.06M 963K 1.81M 122M 1.82M 12.71M 4.91M 62.51M 4.79M 4.69M 201M
Net income -2.5B -78.66M -69.18M -65.42M -59.34M -111M -7.55B -112M -783M -303M -3.85B -295M -289M -12.38B -3.93B -123M -109M -103M -93.11M -175M -11.85B -176M -1.23B -475M -6.05B -463M -453M -19.43B
Net Debt 9.19M 289K 254K 240K 218K 409K 27.73M 412K 2.88M 1.11M 14.15M 1.08M 1.06M 45.48M 517M 16.25M 14.29M 13.51M 12.26M 23.02M 1.56B 23.15M 162M 62.48M 796M 61M 59.67M 2.56B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock